Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. (Nasdaq: INMB) on June 03, 2021, covering events occurring on June 02, 2021. The Company is a Nevada corporation headquartered in La Jolla, California, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance data.
Material Changes
The primary material event reported is the adoption of a generic name for the Company's lead clinical candidate:
- Candidate: XPro1595
- Event: The United States Adopted Name Council (USAN) adopted the generic name "Pegipanermin" for XPro1595.
- Announcement Date: June 02, 2021
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosures inherent in a clinical-stage biopharmaceutical company. The report serves solely to disclose the naming event and includes a press release as Exhibit 99.1.
Investor Verification Checklist
- Verify the clinical development status and trial data for XPro1595 (Pegipanermin) in subsequent filings or press releases.
- Confirm the Company's cash runway and capital requirements in the most recent 10-Q or 10-K, as this 8-K contains no liquidity data.
- Review the full text of the attached press release (Exhibit 99.1) for additional context on the significance of the USAN adoption.